CPL - Chalmers Publication Library
| Utbildning | Forskning | Styrkeområden | Om Chalmers | In English In English Ej inloggad.

Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.

Arvid Edén ; Lars-Magnus Andersson ; Orjan Andersson ; Leo Flamholc ; Filip Josephson ; Staffan Nilsson (Institutionen för matematiska vetenskaper, matematisk statistik) ; Vidar Ormaasen ; Veronica Svedhem ; Christer Säll ; Anders Sönnerborg ; Petra Tunbäck ; Magnus Gisslén
AIDS research and human retroviruses (1931-8405). Vol. 26 (2010), 5, p. 533-40.
[Artikel, refereegranskad vetenskaplig]

Initial viral decay rate may be useful when comparing the relative potency of antiretroviral regimens. Two hundred twenty-seven ART-naïve patients were randomized to receive efavirenz (EFV) (n = 74), lopinavir/ritonavir (LPV/r) (n = 77), or atazanavir/ritonavir (ATV/r) (n = 79) in combination with two NRTIs. The most frequently used NRTI combinations in the EFV and ATV/r groups were the nonthymidine analogues tenofovir and emtricitabine or lamivudine (70% and 68%, respectively) and, in the LPV/r group, lamivudine and the thymidine analogue zidovudine (89%). HIV-1 RNA was monitored during the first 28 days after treatment initiation. Phase 1 and 2 decay rate was estimated in a subset of 157 patients by RNA decrease from days 0 to 7, and days 14 to 28. One-way ANOVA and subsequent Tukey's post hoc tests were used for groupwise comparisons. Mean (95% CI) HIV-1 RNA reductions from days 0 to 28 were 2.59 (2.45-2.73), 2.42 (2.27-2.57), and 2.13 (2.01-2.25) log(10) copies/ml for the EFV-, LPV/r-, and ATV/r-based treatment groups, respectively, with a significantly larger decrease in the EFV-based group at all time points compared with ATV/r (p < 0.0001), and with LPV/r at days 7-21 (p < 0.0001-0.03). LPV/r gave a greater RNA decrease compared with ATV/r from day 14 (p = 0.02). Phase 1 decay rate was significantly higher in the EFV group compared with LPV/r (p = 0.003) or ATV/r (p < 0.0001). No difference was found in phase 2 decrease. EFV-based treatment gave a more rapid decline in HIV-1 RNA than did either of the boosted protease inhibitor-based regimens. The observed differences may reflect different inherent regimen potencies.

Nyckelord: Adult, Aged, Anti-HIV Agents, pharmacology, therapeutic use, Benzoxazines, pharmacology, therapeutic use, Drug Therapy, Combination, Female, HIV Infections, drug therapy, virology, HIV-1, drug effects, Humans, Male, Middle Aged, Oligopeptides, pharmacology, therapeutic use, Pyridines, pharmacology, therapeutic use, Pyrimidinones, pharmacology, therapeutic use, RNA, Viral, blood, drug effects, Reverse Transcriptase Inhibitors, pharmacology, therapeutic use, Treatment Outcome

Denna post skapades 2011-01-19. Senast ändrad 2015-01-16.
CPL Pubid: 135153


Läs direkt!

Länk till annan sajt (kan kräva inloggning)

Institutioner (Chalmers)

Institutionen för biomedicin, avdelningen för infektionssjukdomar (GU)
Institutionen för matematiska vetenskaper, matematisk statistik (2005-2016)
Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för dermatologi och venereologi (GU)


Klinisk virologi

Chalmers infrastruktur